Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience

Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug

(2016) Jacques-Eric Gottenberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Direct Comparative Effectiveness Among 3 Anti–Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis

(2016) Pedro Santos-Moreno et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry

(2016) S. H. M. Manders et al.   JOURNAL OF RHEUMATOLOGY

Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry

(2016) Ennio Giulio Favalli et al.   ARTHRITIS CARE & RESEARCH

Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers

(2015) Thierry Lequerré et al.   JOINT BONE SPINE

Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

(2015) Leslie R. Harrold et al.   ARTHRITIS RESEARCH & THERAPY

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

(2015) Sofie HM Manders et al.   ARTHRITIS RESEARCH & THERAPY

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register

(2014) Katerina Chatzidionysiou et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

(2014) Jackie L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

(2014) P Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice

(2014) Aline Frazier-Mironer et al.   JOINT BONE SPINE

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies

(2014) E. G. Favalli et al.   RHEUMATOLOGY

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab

(2013) M Neovius et al.   ANNALS OF THE RHEUMATIC DISEASES

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

(2013) Y Hishitani et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort

(2013) K Chatzidionysiou et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

(2013) Irini Flouri et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

(2011) M. M. Soliman et al.   ANNALS OF THE RHEUMATIC DISEASES

Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry

(2011) J. A. MARKENSON et al.   JOURNAL OF RHEUMATOLOGY

The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug

(2011) MK Söderlin et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

(2009) A Finckh et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

(2009) Sophie Martin Du Pan et al.   ARTHRITIS AND RHEUMATISM

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

(2009) Merete Lund Hetland et al.   ARTHRITIS AND RHEUMATISM

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

(2009) J. A. Singh et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

(2008) Paul Emery et al.   LANCET